ClinicalTrials.gg
CompletedNCT02189629Updated Nov 14, 2019Results posted

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

A Phase 3 interventional study of CD5789 (trifarotene) in Acne Vulgaris, sponsored by Galderma R&D. Completed at 32 sites in 4 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-14.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Not applicable
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
7th of 12
453 · median 507
Started
2015
with 2 others
Phase 3
6 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 2nd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.

Read the detailed description

To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a secondary objective.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne vulgaris
  • Safety
  • Face
  • Trunk
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The Subject has a facial acne severity grade of IGA grade 3 (moderate) at Screening and Baseline visits.
  • The Subject has a minimum of 20 inflammatory lesions and 25 non-inflammatory lesions at Screening and Baseline visits on the face.

Exclusion criteria

  • The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.).
  • The Subject has more than 1 nodule on the face at Screening and at Baseline visits.
  • The Subject has any acne cyst on the face at Screening and at Baseline visits.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    CD5789 (trifarotene) cream

    Drug: CD5789 (trifarotene)

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment (IGA) Success Rate up to Week 52

    Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (clear).

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Physician Global Assessment (PGA) Success Rate up to Week 52

    Number of subjects who achieved a Physician Global Assessment (PGA) score of 1 (almost clear) or 0 (clear).

    Time frame: From Baseline to Week 52

07

Results

Posted Sep 17, 2019

Participant flow

Participant flow — Overall Study
MilestoneCD5789 Cream
Started453
Completed348
Not completed105

Outcome measures

PrimaryInvestigator Global Assessment (IGA) Success Rate up to Week 52

Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (clear).

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Investigator Global Assessment (IGA) Success Rate up to Week 52
ParticipantsCD5789 Cream
Investigator Global Assessment (IGA) Success Rate up to Week 52453
SecondaryPhysician Global Assessment (PGA) Success Rate up to Week 52

Number of subjects who achieved a Physician Global Assessment (PGA) score of 1 (almost clear) or 0 (clear).

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Physician Global Assessment (PGA) Success Rate up to Week 52
ParticipantsCD5789 Cream
Physician Global Assessment (PGA) Success Rate up to Week 52453

Adverse events

Collected over Over 52 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5789 Cream0/453 (0%)10/453 (2.2%)170/453 (37.5%)
Most frequent serious events
Most frequent serious events
EventCD5789 Cream
Crohn's DiseaseGastrointestinal disorders1/453
Umbilical HerniaGastrointestinal disorders1/453
AppendicitisInfections and infestations1/453
Pyelonephritis AcuteInfections and infestations1/453
Complex partial seizuresNervous system disorders1/453
Complex regional Pain syndromeNervous system disorders1/453
Nasal septum deviationRespiratory, thoracic and mediastinal disorders1/453
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/453
Post procedural haemorrhageInjury, poisoning and procedural complications1/453
Liver function test abnormalInvestigations1/453
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCD5789 Cream
NasopharyngitisInfections and infestations48/453
SunburnInjury, poisoning and procedural complications27/453
Application Site PruritisGeneral disorders23/453
Application Site IrritationGeneral disorders22/453
Upper Respiratory Tract InfectionInfections and infestations13/453
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders9/453
InfluenzaInfections and infestations9/453
Ligament SprainInjury, poisoning and procedural complications6/453
HeadacheNervous system disorders6/453
DiarrheaGastrointestinal disorders5/453

Baseline characteristics

A total of 455 subjects were enrolled and 453 were exposed to CD5789 50 microgram/gram cream for up to 52 weeks.

Age, Categorical
Age, Categorical(Participants)CD5789 Cream
<=18 years286
Between 18 and 65 years167
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)CD5789 Cream
Female226
Male227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD5789 Cream
Hispanic or Latino47
Not Hispanic or Latino406
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5789 Cream
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander3
Black or African American12
White432
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)CD5789 Cream
Hungary91
United States163
Czechia104
Germany95
08

Study locations

32 sites
  • Galderma Investigational Site
    Mobile, Alabama 36608, United States
  • Galderma Investigational Site
    Rogers, Arkansas 72758, United States
  • Galderma Investigational Site
    Sacramento, California 95819, United States
  • Galderma Investigational Site
    San Diego, California 92123, United States
  • Galderma Investigational Site
    Miami, Florida 33175, United States
  • Galderma Investigational Site
    Miramar, Florida 33027, United States
  • Galderma Investigational Site
    Newnan, Georgia 30277, United States
  • Galderma Investigational Site
    Louisville, Kentucky 40241, United States
  • Galderma Investigational Site
    Albuquerque, New Mexico 87107, United States
  • Galderma Investigational Site
    New York, New York 10155, United States
  • Galderma Investigational Site
    High Point, North Carolina 27262, United States
  • Galderma Investigational Site
    Beachwood, Ohio 44122, United States
  • Galderma Investigational Site
    Portland, Oregon 97210, United States
  • Galderma Investigational Site
    Knoxville, Tennessee 37922, United States
  • Galderma Investigational Site
    Chomutov, 430 04, Czechia
  • Galderma Investigational site
    Hradec Kralove, 500 05, Czechia
  • Galderma Investigational Site
    Olomouc, 775 20, Czechia
  • Galderma Investigational Site
    Pardubice, 532 03, Czechia
  • Galderma Investigational site
    Praha 1, 110 00, Czechia
  • Galderma Investigational Site
    Augsburg, 86179, Germany
  • Galderma Investigational Site
    Berlin, 10117, Germany
  • Galderma Investigational Site
    Berlin, 13507, Germany
  • Galderma Investigational Site
    Dessau, 06847, Germany
  • Galderma Investigational Site
    Mahlow, 15831, Germany
  • Galderma Investigational Site
    Muenster, 48149, Germany
  • Galderma Investigational Site
    Wuppertal, 42287, Germany
  • Galderma Investigational Site
    Balatonfüred, 8230, Hungary
  • Galderma Investigational Site
    Miskolc, 3529, Hungary
  • Galderma Investigational Site
    Pécel, 2119, Hungary
  • Galderma Investigational Site
    Szeged, 6720, Hungary
  • Galderma Investigational Site
    Szekszard, 7100, Hungary
  • Galderma Investigational Site
    Szolnok, 5000, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Feb 2017, 24 months.

Results were first posted in Sep 2019, 2 years 6 months after primary completion. A results delay was requested in May 2018.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 24 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2014
First posted
Jul 14, 2014
StartActual
Feb 23, 2015
Primary completionActual
Feb 23, 2017
CompletionActual
Feb 23, 2017
Results delay requested
May 15, 2018
Results first posted
Sep 17, 2019
Last update
Nov 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02189629
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jul 14, 2014
Start date
Feb 23, 2015
Primary completion
Feb 23, 2017
Completion
Feb 23, 2017
Results posted
Sep 17, 2019
Last update
Nov 14, 2019

Study contacts

Kevin Chan
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion